Los Angeles Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$274M Sell
1,260,942
-1,070,687
-46% -$238M 1.08% 12
2025
Q4
$532M Buy
2,331,629
+7,343
+0.3% +$1.67M 1.81% 10
2025
Q3
$538M Buy
2,324,286
+304,281
+15% +$62M 1.83% 10
2025
Q2
$375M Buy
2,020,005
+451,078
+29% +$83.8M 1.4% 12
2025
Q1
$329M Buy
1,568,927
+945,165
+152% +$184M 1.45% 11
2024
Q4
$111M Buy
623,762
+8,264
+1% +$1.52M 0.45% 52
2024
Q3
$122M Buy
615,498
+382,242
+164% +$71.3M 0.49% 47
2024
Q2
$40M Buy
233,256
+64,979
+39% +$10.8M 0.14% 126
2024
Q1
$30.6M Sell
168,277
-147,843
-47% -$25.5M 0.1% 175
2023
Q4
$49M Buy
316,120
+129,355
+69% +$18.9M 0.18% 109
2023
Q3
$27.8M Sell
186,765
-8,209
-4% -$1.21M 0.12% 160
2023
Q2
$26.3M Sell
194,974
-201,509
-51% -$29.5M 0.11% 163
2023
Q1
$63.2M Sell
396,483
-301,332
-43% -$46.1M 0.28% 85
2022
Q4
$113M Sell
697,815
-262,465
-27% -$40.2M 0.55% 45
2022
Q3
$129M Sell
960,280
-267,643
-22% -$38.4M 0.67% 33
2022
Q2
$188M Sell
1,227,923
-47,277
-4% -$7.22M 0.92% 21
2022
Q1
$207M Buy
1,275,200
+344,372
+37% +$50M 0.81% 23
2021
Q4
$126M Buy
930,828
+139,931
+18% +$16.5M 0.47% 49
2021
Q3
$85.3M Sell
790,897
-118,892
-13% -$13.6M 0.39% 60
2021
Q2
$102M Sell
909,789
-56,245
-6% -$6.33M 0.45% 49
2021
Q1
$105M Sell
966,034
-22,116
-2% -$2.37M 0.47% 39
2020
Q4
$106M Sell
988,150
-175,466
-15% -$16.9M 0.45% 41
2020
Q3
$102M Sell
1,163,616
-1,245,840
-52% -$117M 0.47% 42
2020
Q2
$237M Buy
2,409,456
+636,292
+36% +$56M 1.14% 9
2020
Q1
$135M Sell
1,773,164
-1,892,919
-52% -$161M 0.85% 18
2019
Q4
$325M Buy
3,666,083
+1,405,797
+62% +$117M 1.62% 5
2019
Q3
$171M Buy
2,260,286
+1,612,889
+249% +$111M 0.93% 12
2019
Q2
$47.1M Sell
647,397
-137,189
-17% -$10.8M 0.25% 97
2019
Q1
$63.2M Sell
784,586
-186,670
-19% -$15.3M 0.35% 62
2018
Q4
$89.5M Buy
971,256
+337,004
+53% +$29.6M 0.56% 39
2018
Q3
$60M Sell
634,252
-199,300
-24% -$18.9M 0.31% 73
2018
Q2
$77.2M Sell
833,552
-87,259
-9% -$8.52M 0.43% 39
2018
Q1
$87.2M Buy
920,811
+576,810
+168% +$63.4M 0.49% 37
2017
Q4
$33.3M Sell
344,001
-407,229
-54% -$38.4M 0.18% 147
2017
Q3
$66.8M Buy
751,230
+10,838
+1% +$825K 0.38% 62
2017
Q2
$53.7M Buy
740,392
+145,691
+24% +$9.79M 0.34% 69
2017
Q1
$38.8M Buy
594,701
+201,638
+51% +$12.7M 0.28% 95
2016
Q4
$24.6M Buy
393,063
+663
+0.2% +$40.5K 0.19% 155
2016
Q3
$24.7M Sell
392,400
-2,600
-0.7% -$168K 0.21% 145
2016
Q2
$24.5M Sell
395,000
-22,235
-5% -$1.35M 0.21% 133
2016
Q1
$23.8M Buy
417,235
+1,235
+0.3% +$68.8K 0.21% 128
2015
Q4
$24.6M Sell
416,000
-24,610
-6% -$1.42M 0.23% 120
2015
Q3
$24M Buy
440,610
+6,280
+1% +$409K 0.23% 129
2015
Q2
$29.2M Sell
434,330
-134,289
-24% -$8.77M 0.27% 110
2015
Q1
$33.3M Sell
568,619
-105,766
-16% -$6.39M 0.31% 102
2014
Q4
$44.1M Buy
674,385
+40,537
+6% +$2.56M 0.41% 72
2014
Q3
$36.6M Buy
633,848
+92,732
+17% +$5.15M 0.44% 60
2014
Q2
$30.5M Buy
541,116
+58,039
+12% +$3.04M 0.29% 101
2014
Q1
$24.8M Buy
483,077
+20,451
+4% +$1.03M 0.27% 110
2013
Q4
$24.4M Sell
462,626
-39,175
-8% -$1.93M 0.27% 117
2013
Q3
$22.4M Buy
501,801
+106,625
+27% +$4.73M 0.28% 103
2013
Q2
$16.3M Buy
+395,176
New +$17.3M 0.23% 123

Other funds holding ABBV

Los Angeles Capital Management's ABBV Position: Q1 2026 in Review

Los Angeles Capital Management reduced its AbbVie (ABBV) stake by 46% in Q1 2026, selling an estimated $238M and leaving 1,260,942 shares worth $274M. The position accounts for 1.08% of the portfolio, ranked #12.

Los Angeles Capital Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $538M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Los Angeles Capital Management held 1,260,942 shares of AbbVie worth $274M as of Q1 2026.
  • Los Angeles Capital Management sold 1,070,687 AbbVie shares in Q1 2026, an estimated $238M.
  • AbbVie made up 1.08% of Los Angeles Capital Management's portfolio in Q1 2026, its #12 holding.
  • Los Angeles Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Los Angeles Capital Management's AbbVie position peaked at $538M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.